PROTHENA CORP PLC (NASDAQ:PRTA) reported a mixed set of second-quarter 2026 results that stand out for how sharply revenue and earnings diverged from Wall Street expectations: the top line came in dramatically below consensus, while the adjusted per-share loss was narrower than analysts had modeled.
Reported versus estimates
The quarter illustrates why top-line comparisons can be misleading for a clinical-stage biotech that recognizes revenue from collaboration milestones rather than product sales.
- Total revenue: $1.0 million reported versus $28.9 million consensus; a substantial shortfall
- Non-GAAP EPS: -$0.32 reported versus -$0.40 consensus; a meaningful beat
The revenue miss reflects the absence of major milestone payments in the three-month period. In the first half of 2026, by contrast, Prothena recorded a $50.0 million milestone from Novo Nordisk related to the ongoing Phase 3 coramitug trial, which helped push six-month revenue to $52.1 million. Second-quarter 2025 revenue was also modest at $4.4 million, but the current quarter fell even lower as revenue recognition revolved largely around a partial performance obligation on the PRX019 Phase 1 study with Bristol Myers Squibb.
On the bottom line, the wider consensus loss estimate was driven by expectations of heavier R&D spending. Prothena kept a tight rein on expenses in the quarter, with research and development costs dropping to $8.8 million from $40.5 million a year earlier and general and administrative costs falling to $10.9 million from $15.9 million. That contraction, combined with a $2.4 million restructuring charge, still produced a net loss of $18.6 million, better than the market’s forecast.
What the price action shows
Market reaction has been muted at the headline level. The stock is up about 2.0% over the past week, but remains roughly 11% lower over the last month, suggesting investors are still weighing the improved cost discipline against the sharply lower revenue quarter. The absence of a large aftermarket move points to a market that may have already discounted much of the quarterly volatility in a company whose revenue line depends on partnership milestones and trial progress.
Guidance and outlook
Prothena reiterated its full-year 2026 net cash used in operating and investing activities guidance of $18 million to $23 million and updated its projected year-end cash balance to approximately $259 million at the midpoint, down from the prior $273 million midpoint largely due to share repurchases.
Key guidance points from the release:
- Full-year net loss expected between $25 million and $30 million
- Non-cash share-based compensation of approximately $26 million embedded in that loss
- Potential $55 million PRX019 clinical milestone payment excluded from guidance
- Full-year 2026 revenue guidance not provided
The lack of formal revenue guidance is consistent with the company’s reliance on collaboration milestones, whose timing is hard to predict. Consensus currently models 2026 revenue near $86.4 million, a level that would require substantial milestone activity in the back half of the year. Management’s net loss view suggests the company is still planning for meaningful investment in its wholly owned and partnered pipeline, despite the sharply lower spending seen in the first half.
Other financial highlights from the release
Quarterly cash flow and capital returns were also notable:
- Cash, cash equivalents and restricted cash stood at $289.1 million as of June 30, 2026, with no debt
- Prothena repurchased 1,454,898 ordinary shares in the second quarter, contributing to 2.24 million shares repurchased in the first half for $22.3 million
- Approximately 51.3 million ordinary shares were outstanding as of July 30, 2026
The share repurchase program, which expires on December 31, 2026, gives management a mechanism to return capital even while clinical-stage losses continue.
Investors looking for more detail on prior quarterly financial performance can review the historical earnings information available here. For a view of how sell-side models are evolving heading into the next reporting periods, future estimates and projections can be found on this page.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Prothena (NASDAQ:PRTA) Beats EPS but Misses Revenue in Mixed Q2 2026 Results
PROTHENA CORP PLC (NASDAQ:PRTA) reported a mixed set of second-quarter 2026 results that stand out for how sharply revenue and earnings diverged from Wall Street expectations: the top line came in dramatically below consensus, while the adjusted per-share loss was narrower than analysts had modeled.
Reported versus estimates
The quarter illustrates why top-line comparisons can be misleading for a clinical-stage biotech that recognizes revenue from collaboration milestones rather than product sales.
The revenue miss reflects the absence of major milestone payments in the three-month period. In the first half of 2026, by contrast, Prothena recorded a $50.0 million milestone from Novo Nordisk related to the ongoing Phase 3 coramitug trial, which helped push six-month revenue to $52.1 million. Second-quarter 2025 revenue was also modest at $4.4 million, but the current quarter fell even lower as revenue recognition revolved largely around a partial performance obligation on the PRX019 Phase 1 study with Bristol Myers Squibb.
On the bottom line, the wider consensus loss estimate was driven by expectations of heavier R&D spending. Prothena kept a tight rein on expenses in the quarter, with research and development costs dropping to $8.8 million from $40.5 million a year earlier and general and administrative costs falling to $10.9 million from $15.9 million. That contraction, combined with a $2.4 million restructuring charge, still produced a net loss of $18.6 million, better than the market’s forecast.
What the price action shows
Market reaction has been muted at the headline level. The stock is up about 2.0% over the past week, but remains roughly 11% lower over the last month, suggesting investors are still weighing the improved cost discipline against the sharply lower revenue quarter. The absence of a large aftermarket move points to a market that may have already discounted much of the quarterly volatility in a company whose revenue line depends on partnership milestones and trial progress.
Guidance and outlook
Prothena reiterated its full-year 2026 net cash used in operating and investing activities guidance of $18 million to $23 million and updated its projected year-end cash balance to approximately $259 million at the midpoint, down from the prior $273 million midpoint largely due to share repurchases.
Key guidance points from the release:
The lack of formal revenue guidance is consistent with the company’s reliance on collaboration milestones, whose timing is hard to predict. Consensus currently models 2026 revenue near $86.4 million, a level that would require substantial milestone activity in the back half of the year. Management’s net loss view suggests the company is still planning for meaningful investment in its wholly owned and partnered pipeline, despite the sharply lower spending seen in the first half.
Other financial highlights from the release
Quarterly cash flow and capital returns were also notable:
The share repurchase program, which expires on December 31, 2026, gives management a mechanism to return capital even while clinical-stage losses continue.
Investors looking for more detail on prior quarterly financial performance can review the historical earnings information available here. For a view of how sell-side models are evolving heading into the next reporting periods, future estimates and projections can be found on this page.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »